SURPASS-CVOT randomized 13,299 patients with T2D and established ASCVD to tirzepatide up to 15 mg weekly versus dulaglutide 1 ...

Jeffrey Turner, MD, discusses the discovery of cardiovascular and renal benefits in SGLT2 inhibitors, and Nihar R. Desai, MD, MPH, provides insight into the role of SGLT2 inhibitors in the four ...

Cardiorenal disease represents a major global health challenge, characterized by the intricate interplay between cardiovascular and renal dysfunction.

Please provide your email address to receive an email when new articles are posted on . The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart ...

To recognize and describe the complicated interactions between these organ systems, we have devised a classification of CRS with four subtypes, in which the etymology reflects the probable primary and ...

AstraZeneca will acquire CinCor Pharma in a deal that aims to boost the British pharma giant’s cardiorenal pipeline, the company announced Monday. The $1.8 billion deal will give AstraZeneca CinCor’s ...

A key feature of the release is a more precise ultrafiltration adjustment capability, reducing the step size to 5 mL/hr from 10 mL/hr. This advancement is particularly important in pediatric care, ...

GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...

The use of SGLT2 inhibitors in people with type 2 diabetes (T2D) who also have liver cirrhosis led to reductions in the risks for end-stage kidney disease (ESKD), acute kidney injury (AKI), and major ...

The mortality and morbidity of congestive heart failure (CHF) have improved slightly over the years but are still very high. Many patients with CHF are anemic, which raises the question, 'Could ...

Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. We therefore implemented a detailed, prospective, clinical ...

Welcoming back Liby, Meredith, and Scott reflects the strength of our team and the culture we are building at Nuwellis,” said Nuwellis’ CEO John Erb. “Each of them brings deep experience, strong ...